Pub Date : 2024-07-02DOI: 10.48208/headachemed.2024.11
Marcelo Moraes Valença, M. Peres
I n the busy and often overcrowded emergency services environment, the Manchester Triage System (MTS) plays a crucial role in saving lives and optimizing care. Initially developed at the Manchester Royal Infirmary in 1997, this innovative system enhances care in emergency departments by ensuring that patients needing immediate attention receive the required priority (1, 2). Since its implementation, the Manchester Triage System has improved workflows and patient safety and set a global standard, being adopted as a standard protocol in numerous hospitals across the UK and beyond (1). Despite its widespread adoption and initial success, recent evaluations and studies suggest that the system might be failing to manage certain critical cases (3, 4), particularly those involving severe headaches such as migraines and cluster headaches. These conditions, often debilitating and intensely painful, require prompt and effective treatment, yet under the current triage protocol, they may not be prioritized appropriately.
{"title":"Rethinking triage: enhancing the Manchester Triage System for headache emergencies","authors":"Marcelo Moraes Valença, M. Peres","doi":"10.48208/headachemed.2024.11","DOIUrl":"https://doi.org/10.48208/headachemed.2024.11","url":null,"abstract":"I n the busy and often overcrowded emergency services environment, the Manchester Triage System (MTS) plays a crucial role in saving lives and optimizing care. Initially developed at the Manchester Royal Infirmary in 1997, this innovative system enhances care in emergency departments by ensuring that patients needing immediate attention receive the required priority (1, 2). Since its implementation, the Manchester Triage System has improved workflows and patient safety and set a global standard, being adopted as a standard protocol in numerous hospitals across the UK and beyond (1). Despite its widespread adoption and initial success, recent evaluations and studies suggest that the system might be failing to manage certain critical cases (3, 4), particularly those involving severe headaches such as migraines and cluster headaches. These conditions, often debilitating and intensely painful, require prompt and effective treatment, yet under the current triage protocol, they may not be prioritized appropriately.","PeriodicalId":12925,"journal":{"name":"Headache Medicine","volume":"359 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141686458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-01DOI: 10.48208/headachemed.2024.6
R. Silva-Néto, Bianca Piloni, Luan Almeida
Introduction: Migraine is a chronic neurological disease, with a prevalence of 15.2% in Brazil. It is defined as an abnormal neurovascular reaction that occurs in a genetically vulnerable individual. Clinically manifests itself in recurrent episodes of headache associated with other symptoms, dependent on triggering factors. Objective: To describe the epidemiological profile of hospital admissions of children and adolescents for migraine and other headache disorders. Methods: This was a retrospective and descriptive epidemiological study carried out with data extracted from the Brazilian Unified Health System's Hospital Information System (SIH/SUS), indexed to the Department of Informatics of the Unified Health System (DATASUS). Hospital admissions were selected based on age groups, with an emphasis on children under nine years old and adolescents between 10 and 19 years old, residing in Brazil, between July 2013 and June 2023. Results: Of 93,821 hospital admissions, there were 16,149 hospitalizations (17.2%) of children and adolescents (62.5% women and 37.5% men) due to migraine and other headache disorders. There was a predominance of the age group between 15 and 19 years old (50.2%), with a higher number of cases in the Southeast region (35.9%) and of brown ethnicity (42.6%). Over 10 years, there was a progressive increase in the number of hospital admissions, reaching a peak in 2019 (1,925/16,149; 11.9%), followed by a decline in 2020 and increasing again in subsequent years. Twenty-four deaths were found (24/16,149; 0.1%), 13 men and 11 women, with a predominance in the age group of 15 to 19 years (45.8%), coming from the Northeast region (58.3 %) and of brown ethnicity (58.4%). Deaths occurred predominantly in the years 2022 and 2023 (46.6%). Conclusions: There is an increase in the number of hospital admissions of children and adolescents due to migraine and other headache disorders with a consequent increase in the number of deaths.
{"title":"Profile of hospital admissions for migraine and other headache syndromes in children and adolescents in Brazil between 2013 and 2023","authors":"R. Silva-Néto, Bianca Piloni, Luan Almeida","doi":"10.48208/headachemed.2024.6","DOIUrl":"https://doi.org/10.48208/headachemed.2024.6","url":null,"abstract":"Introduction: Migraine is a chronic neurological disease, with a prevalence of 15.2% in Brazil. It is defined as an abnormal neurovascular reaction that occurs in a genetically vulnerable individual. Clinically manifests itself in recurrent episodes of headache associated with other symptoms, dependent on triggering factors. Objective: To describe the epidemiological profile of hospital admissions of children and adolescents for migraine and other headache disorders. Methods: This was a retrospective and descriptive epidemiological study carried out with data extracted from the Brazilian Unified Health System's Hospital Information System (SIH/SUS), indexed to the Department of Informatics of the Unified Health System (DATASUS). Hospital admissions were selected based on age groups, with an emphasis on children under nine years old and adolescents between 10 and 19 years old, residing in Brazil, between July 2013 and June 2023. Results: Of 93,821 hospital admissions, there were 16,149 hospitalizations (17.2%) of children and adolescents (62.5% women and 37.5% men) due to migraine and other headache disorders. There was a predominance of the age group between 15 and 19 years old (50.2%), with a higher number of cases in the Southeast region (35.9%) and of brown ethnicity (42.6%). Over 10 years, there was a progressive increase in the number of hospital admissions, reaching a peak in 2019 (1,925/16,149; 11.9%), followed by a decline in 2020 and increasing again in subsequent years. Twenty-four deaths were found (24/16,149; 0.1%), 13 men and 11 women, with a predominance in the age group of 15 to 19 years (45.8%), coming from the Northeast region (58.3 %) and of brown ethnicity (58.4%). Deaths occurred predominantly in the years 2022 and 2023 (46.6%). Conclusions: There is an increase in the number of hospital admissions of children and adolescents due to migraine and other headache disorders with a consequent increase in the number of deaths.","PeriodicalId":12925,"journal":{"name":"Headache Medicine","volume":"57 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140768184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-21DOI: 10.48208/headachemed.2023.15
Renata Gomes Londero
Afetando 1-2% da população mundial e representado até 40% dos pacientes em serviços especializados em cefaleia, a cefaleia por uso excessivo de medicamentos segue um desafio. Iniciando pela necessidade de conscientizar os profissionais desde a atenção básica, passando pela educação do paciente e finalizando pelo adequado (e de sucesso) manejo, ainda há muito o que fazer na área. Esta revisão da literatura, busca alertar não apenas para a importância do reconhecimento da condição mas principalmente trazer o que há de mais recente no melhor manejo dos pacientes que padecem com dores mais de 14 dias por mês e que ainda vêem os analgésicos como única forma de tratamento.
{"title":"Esteja alerta para a possibilidade de cefaleia por uso excessivo de medicamentos","authors":"Renata Gomes Londero","doi":"10.48208/headachemed.2023.15","DOIUrl":"https://doi.org/10.48208/headachemed.2023.15","url":null,"abstract":"Afetando 1-2% da população mundial e representado até 40% dos pacientes em serviços especializados em cefaleia, a cefaleia por uso excessivo de medicamentos segue um desafio. Iniciando pela necessidade de conscientizar os profissionais desde a atenção básica, passando pela educação do paciente e finalizando pelo adequado (e de sucesso) manejo, ainda há muito o que fazer na área. Esta revisão da literatura, busca alertar não apenas para a importância do reconhecimento da condição mas principalmente trazer o que há de mais recente no melhor manejo dos pacientes que padecem com dores mais de 14 dias por mês e que ainda vêem os analgésicos como única forma de tratamento.","PeriodicalId":12925,"journal":{"name":"Headache Medicine","volume":"20 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139356779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-31DOI: 10.48208/headachemed.2023.2
Wallyson Pablo de Oliveira Souza, Yasmine Maria Leódido Fortes, A. Soares, R. Silva-Néto
IntroductionPropranolol was the first non-selective beta-adrenergic blocker to be developed. Initially it was used in the treatment of cardiovascular diseases, but since the 60's it has been used in the prevention of migraine.ObjectiveThe objective of this study was to know the history of propranolol and its use as a migraine prophylactic.MethodsThis study was an integrative literature review using articles with historical data on propranolol, from its origin in cardiology to its indication in the preventive treatment of migraine.ResultsPropranolol was described in 1962 for the treatment of cardiovascular diseases. In the same decade, it was prescribed for the preventive treatment of migraine and, recently, included in the consensus of the Brazilian Headache Society.ConclusionAlthough propranolol was initially synthesized for the treatment of heart disease, it has proved to be an effective drug in preventing migraine attacks.
{"title":"Propranolol: A migraine prophylactic since the 1960s","authors":"Wallyson Pablo de Oliveira Souza, Yasmine Maria Leódido Fortes, A. Soares, R. Silva-Néto","doi":"10.48208/headachemed.2023.2","DOIUrl":"https://doi.org/10.48208/headachemed.2023.2","url":null,"abstract":"IntroductionPropranolol was the first non-selective beta-adrenergic blocker to be developed. Initially it was used in the treatment of cardiovascular diseases, but since the 60's it has been used in the prevention of migraine.ObjectiveThe objective of this study was to know the history of propranolol and its use as a migraine prophylactic.MethodsThis study was an integrative literature review using articles with historical data on propranolol, from its origin in cardiology to its indication in the preventive treatment of migraine.ResultsPropranolol was described in 1962 for the treatment of cardiovascular diseases. In the same decade, it was prescribed for the preventive treatment of migraine and, recently, included in the consensus of the Brazilian Headache Society.ConclusionAlthough propranolol was initially synthesized for the treatment of heart disease, it has proved to be an effective drug in preventing migraine attacks.","PeriodicalId":12925,"journal":{"name":"Headache Medicine","volume":"89 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80842679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-31DOI: 10.48208/headachemed.2023.5
Claudia Baptista Tavares, D. A. D. Oliveira, Manuella Moraes Monteiro Barbosa Barros, J. Souza, P. M. Moreira Filho
IntroductionMigraine is a complex headache to treat, often with an unsatisfactory clinical response. Aerobic exercise, such as running, can be a non-pharmacological treatment to reduce migraine attacks.ObjectiveThis systematic review with meta-analysis investigated the effects of running on frequency and intensity of pain in subjects with migraine compared with other or no aerobic exercise.MethodsRandomized and quasi-randomized clinical trials were searched between September and November 2021 in BVS, PubMed, Cochrane, CINAHL, SCOPUS, Embase, and Web of Science databases. The Cochrane Risk of Bias tool assessed methodological quality, and the recommendation ranking assessed the certainty of evidence. The frequency of migraine attacks was pooled in a meta-analysis (random effects) that included interval and continuous running subgroups.ConclusionThe results were not sufficient to recommend running as a treatment to reduce the frequency and intensity of migraine attacks.
偏头痛是一种复杂的头痛治疗，往往有不满意的临床反应。有氧运动，如跑步，可以是一种减少偏头痛发作的非药物治疗方法。目的本系统综述结合荟萃分析探讨了与其他或无有氧运动相比，跑步对偏头痛患者疼痛频率和强度的影响。方法于2021年9月至11月在BVS、PubMed、Cochrane、CINAHL、SCOPUS、Embase和Web of Science数据库中检索随机和准随机临床试验。Cochrane偏倚风险工具评估方法学质量，推荐排序评估证据的确定性。偏头痛发作的频率汇总在一项荟萃分析中(随机效应)，其中包括间歇和连续跑步亚组。结论本研究结果不足以推荐将跑步作为一种减少偏头痛发作频率和强度的治疗方法。
{"title":"Does running reduce the frequency and intensity of migraine attacks? A systematic review with meta-analysis","authors":"Claudia Baptista Tavares, D. A. D. Oliveira, Manuella Moraes Monteiro Barbosa Barros, J. Souza, P. M. Moreira Filho","doi":"10.48208/headachemed.2023.5","DOIUrl":"https://doi.org/10.48208/headachemed.2023.5","url":null,"abstract":"IntroductionMigraine is a complex headache to treat, often with an unsatisfactory clinical response. Aerobic exercise, such as running, can be a non-pharmacological treatment to reduce migraine attacks.ObjectiveThis systematic review with meta-analysis investigated the effects of running on frequency and intensity of pain in subjects with migraine compared with other or no aerobic exercise.MethodsRandomized and quasi-randomized clinical trials were searched between September and November 2021 in BVS, PubMed, Cochrane, CINAHL, SCOPUS, Embase, and Web of Science databases. The Cochrane Risk of Bias tool assessed methodological quality, and the recommendation ranking assessed the certainty of evidence. The frequency of migraine attacks was pooled in a meta-analysis (random effects) that included interval and continuous running subgroups.ConclusionThe results were not sufficient to recommend running as a treatment to reduce the frequency and intensity of migraine attacks.","PeriodicalId":12925,"journal":{"name":"Headache Medicine","volume":"27 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73316356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-31DOI: 10.48208/headachemed.2023.13
R. Reis, Regina Lúcia Gomes Botter, M. Ferreira, S. L. Souza, J. Andrade, S. L. T. Christensen, M. Valença
ObjectiveTo evaluate mast cell presence in the pericranium of Wistar rats.MethodsFive male rats of the Wistar strain were used. The animals were housed under a 12 h light cycle with ad libitum access to food and water and allowed 10 days of acclimatization before tissue sampling. The five rats were anesthetized by intraperitoneal injection of ketamine/xylazine, 10/20 mg/kg. Following aseptic preparation of the head skin, a midline longitudinal incision was made to expose the pericranium. Two samples of the pericranium were taken, one from the right and one from the left. These samples were fixed in 10% buffered formaldehyde for 24 h. After fixation, tissue samples were paraffin-embedded and sectioned at 4 μm. Then, slides were deparaffinized, stained with a concentration of 0.1% toluidine blue for 1 min, and washed with distilled water. Last, slides were photomicrographed under 400x magnification to identify mast cells.ResultsMast cells were identified in the dura mater and the five rats' pericranium. In the dura mater, mast cells were also found in these rats. We found both granulated (intact) and degranulated mast cells.ConclusionWe suggest that future preclinical studies investigating the involvement of dural mast cells and other meningeal cell populations should also include pericranium samples to explore this structure's relevance in migraine pain and other headache disorders.
{"title":"Presence of mast cells in the rat pericranium – a tissue very sensitive to pain","authors":"R. Reis, Regina Lúcia Gomes Botter, M. Ferreira, S. L. Souza, J. Andrade, S. L. T. Christensen, M. Valença","doi":"10.48208/headachemed.2023.13","DOIUrl":"https://doi.org/10.48208/headachemed.2023.13","url":null,"abstract":"ObjectiveTo evaluate mast cell presence in the pericranium of Wistar rats.MethodsFive male rats of the Wistar strain were used. The animals were housed under a 12 h light cycle with ad libitum access to food and water and allowed 10 days of acclimatization before tissue sampling. The five rats were anesthetized by intraperitoneal injection of ketamine/xylazine, 10/20 mg/kg. Following aseptic preparation of the head skin, a midline longitudinal incision was made to expose the pericranium. Two samples of the pericranium were taken, one from the right and one from the left. These samples were fixed in 10% buffered formaldehyde for 24 h. After fixation, tissue samples were paraffin-embedded and sectioned at 4 μm. Then, slides were deparaffinized, stained with a concentration of 0.1% toluidine blue for 1 min, and washed with distilled water. Last, slides were photomicrographed under 400x magnification to identify mast cells.ResultsMast cells were identified in the dura mater and the five rats' pericranium. In the dura mater, mast cells were also found in these rats. We found both granulated (intact) and degranulated mast cells.ConclusionWe suggest that future preclinical studies investigating the involvement of dural mast cells and other meningeal cell populations should also include pericranium samples to explore this structure's relevance in migraine pain and other headache disorders.","PeriodicalId":12925,"journal":{"name":"Headache Medicine","volume":"180 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81809028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-31DOI: 10.48208/headachemed.2023.8
Aline Vitali da Silva, Marianne Klock Peçanha, Amanda Pasquini de Freitas, V. A. Bello, Regina Célia Poli
IntroductionThe aim of this study was to investigate how infection with SARS-CoV-2 affected headache in individuals with migraine, and to identify characteristics associated with a worsening of the migraine post COVID-19.MethodsObservational study composed of 157 individuals with migraine and who had been infected with the SARS-CoV-2 virus. They were recruited from the database of the headache research group at the Pontifical Catholic University of Paraná. The participants responded online to questions about their anthropometric data, history of infection with SARS-CoV-2, presence and characteristics of the headache in the acute phase, perception of a worsening of the migraine after infection, use of analgesics and prophylactic migraine medication. Validated digital questionnaires were used: Migraine Disability Assessment (MIDAS), Beck Depression Inventory (BDI) and Allodynia Symptom Checklist (ASC-12). The results of these questionnaires were compared to values previously recorded in the database, this information having been obtained prior to the infection with COVID-19.ConclusionIndividuals who notice a worsening in migraine post-COVID-19 have a more severe migraine condition prior to infection, have more prominent headache during the acute phase and, subsequently, present with greater disability.
{"title":"Headache changes in individuals with migraine post-Covid-19: general characteristics of the acute phase and worsening of the migraine pattern","authors":"Aline Vitali da Silva, Marianne Klock Peçanha, Amanda Pasquini de Freitas, V. A. Bello, Regina Célia Poli","doi":"10.48208/headachemed.2023.8","DOIUrl":"https://doi.org/10.48208/headachemed.2023.8","url":null,"abstract":"IntroductionThe aim of this study was to investigate how infection with SARS-CoV-2 affected headache in individuals with migraine, and to identify characteristics associated with a worsening of the migraine post COVID-19.MethodsObservational study composed of 157 individuals with migraine and who had been infected with the SARS-CoV-2 virus. They were recruited from the database of the headache research group at the Pontifical Catholic University of Paraná. The participants responded online to questions about their anthropometric data, history of infection with SARS-CoV-2, presence and characteristics of the headache in the acute phase, perception of a worsening of the migraine after infection, use of analgesics and prophylactic migraine medication. Validated digital questionnaires were used: Migraine Disability Assessment (MIDAS), Beck Depression Inventory (BDI) and Allodynia Symptom Checklist (ASC-12). The results of these questionnaires were compared to values previously recorded in the database, this information having been obtained prior to the infection with COVID-19.ConclusionIndividuals who notice a worsening in migraine post-COVID-19 have a more severe migraine condition prior to infection, have more prominent headache during the acute phase and, subsequently, present with greater disability.","PeriodicalId":12925,"journal":{"name":"Headache Medicine","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89487294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-31DOI: 10.48208/headachemed.2023.4
Henry Martins Soares Fortes, Clênia Leite Andrade
IntroductionAttention deficit hyperactivity disorder (ADHD) has been related to the presence of primary headaches. Among them, migraine presents a wide range of comorbidities shared with ADHD, both from other psychiatric disorders and somatic conditions.ObjectiveThis review proposes to describe the association between ADHD and migraine.MethodsBased on literature research in the major medical databases and using as descriptors “Migraine Disorders” and “Attention Deficit Disorder with Hyperactivity”. Observational studies that addressed the relationship between migraine and ADHD and written only in English were included. Of the 49 articles found, only 6 met the inclusion criteria and were analyzed.ConclusionThis review shows a possible sharing of symptoms between migraine and ADHD, requiring further studies to investigate this relationship.
{"title":"Association between attention deficit hyperactivity disorder (ADHD) and migraine: a review of observational studies","authors":"Henry Martins Soares Fortes, Clênia Leite Andrade","doi":"10.48208/headachemed.2023.4","DOIUrl":"https://doi.org/10.48208/headachemed.2023.4","url":null,"abstract":"IntroductionAttention deficit hyperactivity disorder (ADHD) has been related to the presence of primary headaches. Among them, migraine presents a wide range of comorbidities shared with ADHD, both from other psychiatric disorders and somatic conditions.ObjectiveThis review proposes to describe the association between ADHD and migraine.MethodsBased on literature research in the major medical databases and using as descriptors “Migraine Disorders” and “Attention Deficit Disorder with Hyperactivity”. Observational studies that addressed the relationship between migraine and ADHD and written only in English were included. Of the 49 articles found, only 6 met the inclusion criteria and were analyzed.ConclusionThis review shows a possible sharing of symptoms between migraine and ADHD, requiring further studies to investigate this relationship.","PeriodicalId":12925,"journal":{"name":"Headache Medicine","volume":"25 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73988190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-31DOI: 10.48208/headachemed.2023.3
Anne Lee, R. Domingues
Cranial nerve blocks (CNBs) have been used for the acute and preventive treatment of a variety of headaches, including migraine. The effectiveness of CNBs in migraine is usually observed beyond the duration of the nerve block, possibly due to central pain modulation. The most used target is the greater occipital nerve. Other commonly targeted nerves are the lesser occipital nerve and various branches of the trigeminal nerve, including the supratrochlear, supraorbital, and auriculotemporal nerves. CNBs are generally safe and well-tolerated procedures that can be performed in either emergency or outpatient settings. There is currently no guideline standardizing CNBs in migraine. In clinical practice, as well as the few published studies, the results are encouraging, justifying further studies in the area. In the present study we critically review the literature about the safety and efficacy of CNBs in the treatment of migraine attacks and in the preventive treatment of migraine.
{"title":"The effectiveness and safety of cranial nerve block in migraine: a critical review","authors":"Anne Lee, R. Domingues","doi":"10.48208/headachemed.2023.3","DOIUrl":"https://doi.org/10.48208/headachemed.2023.3","url":null,"abstract":"Cranial nerve blocks (CNBs) have been used for the acute and preventive treatment of a variety of headaches, including migraine. The effectiveness of CNBs in migraine is usually observed beyond the duration of the nerve block, possibly due to central pain modulation. The most used target is the greater occipital nerve. Other commonly targeted nerves are the lesser occipital nerve and various branches of the trigeminal nerve, including the supratrochlear, supraorbital, and auriculotemporal nerves. CNBs are generally safe and well-tolerated procedures that can be performed in either emergency or outpatient settings. There is currently no guideline standardizing CNBs in migraine. In clinical practice, as well as the few published studies, the results are encouraging, justifying further studies in the area. In the present study we critically review the literature about the safety and efficacy of CNBs in the treatment of migraine attacks and in the preventive treatment of migraine.","PeriodicalId":12925,"journal":{"name":"Headache Medicine","volume":"43 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82077778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：